Imexpharm Future Growth

Future criteria checks 3/6

Imexpharm is forecast to grow earnings and revenue by 31.9% and 13.1% per annum respectively while EPS is expected to grow by 32.9% per annum.

Key information

31.9%

Earnings growth rate

32.9%

EPS growth rate

Pharmaceuticals earnings growth17.1%
Revenue growth rate13.1%
Future return on equityn/a
Analyst coverage

Low

Last updated23 Aug 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

HOSE:IMP - Analysts future estimates and past financials data (VND Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20252,561,500378,000N/A336,0002
12/31/20242,292,000327,000N/A360,5002
9/30/20242,161,215229,628158,658239,210N/A
6/30/20242,083,396226,92417,10968,104N/A
3/31/20242,005,866240,873-86,744-26,284N/A
12/31/20231,994,037254,623-103,064-39,535N/A
9/30/20231,943,044262,780-103,565-40,471N/A
6/30/20231,893,973248,8648,49096,011N/A
3/31/20231,808,733212,500158,215259,703N/A
12/31/20221,643,707183,844279,250378,603N/A
9/30/20221,483,063193,294297,677395,679N/A
6/30/20221,321,432168,823270,162341,411N/A
3/31/20221,284,405176,146223,927270,927N/A
12/31/20211,266,597173,513182,024234,881N/A
9/30/20211,357,095173,320171,377251,569N/A
6/30/20211,390,894192,89465,544158,384N/A
3/31/20211,362,172184,24235,719127,814N/A
12/31/20201,369,422179,658-16,53173,153N/A
9/30/20201,398,480164,014-56,80730,791N/A
6/30/20201,436,011154,63649,115141,807N/A
3/31/20201,432,983145,35443,102148,864N/A
12/31/20191,402,454142,900-64,53566,590N/A
9/30/20191,261,051131,865-38,88293,724N/A
6/30/20191,230,077125,694-41,86995,652N/A
3/31/20191,204,780124,885-103,57065,352N/A
12/31/20181,184,818122,041-140,346132,094N/A
9/30/20181,224,760112,394-212,04299,254N/A
6/30/20181,178,882106,176N/A-12,288N/A
3/31/20181,194,327109,745N/A105,208N/A
12/31/20171,165,456103,277N/A97,213N/A
9/30/20171,116,855110,222N/A16,911N/A
6/30/20171,081,387104,160N/A89,001N/A
3/31/20171,041,96790,389N/A46,888N/A
12/31/20161,010,34688,009N/A84,651N/A
9/30/2016979,58775,696N/A153,940N/A
6/30/2016948,20870,215N/A132,462N/A
3/31/2016941,85778,639N/A59,986N/A
12/31/2015964,31981,760N/A44,799N/A
9/30/2015935,08581,196N/A-11,198N/A
6/30/2015968,85384,855N/A20,390N/A
3/31/2015937,56176,918N/A48,563N/A
12/31/2014897,13672,933N/A15,604N/A
9/30/2014825,30553,276N/A75,409N/A
6/30/2014809,11051,677N/A115,213N/A
3/31/2014830,00755,051N/A135,143N/A
12/31/2013841,31660,624N/A128,040N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMP's forecast earnings growth (31.9% per year) is above the savings rate (3%).

Earnings vs Market: IMP's earnings (31.9% per year) are forecast to grow faster than the VN market (20.2% per year).

High Growth Earnings: IMP's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: IMP's revenue (13.1% per year) is forecast to grow slower than the VN market (17.8% per year).

High Growth Revenue: IMP's revenue (13.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IMP's Return on Equity is forecast to be high in 3 years time


Discover growth companies